Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2016-01-26 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 26, 2016, announcing that the results of a Phase III clinical study for the drug Dysport® have been published in the scientific journal *Pediatrics*. The text details the study's positive outcomes (efficacy and safety) and includes quotes from R&D leadership and the principal investigator. This format—a formal announcement about the publication of scientific/clinical data, rather than the full financial report (10-K, IR) or a transcript (CT)—strongly suggests it is an Investor Presentation (IP) or a general press release announcing a significant corporate/scientific event. Since it is a detailed announcement of clinical trial results intended for investors and the public, and it is not a standard regulatory filing like 10-K or a simple earnings release (ER), it fits best under Investor Presentation (IP) as it presents detailed data and strategic information, or potentially Regulatory Filings (RNS) if it were a more generic announcement. Given the depth of the clinical data summary and the focus on communicating scientific milestones to the investment community, IP is a strong candidate. However, since this is a press release announcing the publication of third-party data (in a journal), and it is not a formal investor presentation deck, the most appropriate general category for non-standard, significant corporate news that isn't strictly financial reporting or management change is often RNS (Regulatory Filings/General Announcement). Reviewing the definitions, it is not an ER (which is usually quarterly results), nor an IP (which is usually a deck). It is a formal announcement of a scientific milestone. In many databases, such detailed scientific press releases fall under a general announcement category. Given the options, and recognizing it's a formal communication about a key corporate development (drug trial results), RNS (Regulatory Filings/General Announcement) serves as the best fit for a non-standard, material announcement that isn't explicitly covered elsewhere, although IP is plausible if this were part of a broader investor relations package. I will classify it as RNS as it is a general regulatory/material announcement.
2016-01-26 French
Communicated under the obligation to provide permanent information / Other communications
Environmental & Social Information Classification · 99% confidence The document is a press release from Ipsen dated January 26, 2016, announcing that the detailed results of a Phase III study for their drug Dysport® have been published in the scientific journal *Pediatrics*. The text details the study's primary and secondary endpoints, efficacy, safety profile, and includes quotes from R&D leadership and the Principal Investigator. It is not the full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It is a specific announcement about scientific data being made public. Since it is a detailed announcement of clinical trial results and their publication in a peer-reviewed journal, it most closely aligns with a general scientific or investor-focused update. Given the options, it is a detailed communication aimed at investors and the scientific community regarding clinical data, making 'Investor Presentation' (IP) a plausible fit if it were a presentation deck, but since it is a press release announcing the publication of data, and not a formal regulatory filing like 10-K or a standard earnings report, it falls best under a general regulatory/information release. However, the content is highly specific scientific/clinical data dissemination. If we must choose from the provided list, and recognizing that it is a detailed communication of results rather than just a brief announcement of a report's availability (RPA), it functions as a detailed update for investors. Since it is not a formal presentation (IP) but a press release detailing results, and it's not a standard financial report, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate announcements, or potentially 'Investor Presentation' (IP) if we interpret 'presentation' broadly as 'detailed disclosure'. Given the focus on scientific results and publication, and lack of a specific 'Scientific Publication Announcement' code, RNS is the safest fallback for a significant, non-financial-reporting announcement. However, the depth of the data presentation suggests it is intended to inform investors about a key development, similar to an Investor Presentation's function, but in press release format. Let's re-evaluate: It is a press release announcing the publication of study results. This is a form of corporate communication that doesn't fit 10-K, ER, or IR. It is not a proxy statement (PSI) or dividend notice (DIV). It is a detailed disclosure of R&D success. In many databases, such detailed scientific announcements are categorized under Investor Relations materials. 'Investor Presentation' (IP) is the closest fit for detailed disclosure of clinical/scientific progress, even if the format is a press release rather than a slide deck. I will classify it as IP due to the detailed nature of the scientific findings being shared.
2016-01-26 English
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of December 31, 2015. This specific type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a regulatory disclosure concerning ownership structure, but it is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ) which focus on specific transactions or thresholds. Given the options, this type of routine, mandatory disclosure about the total capital structure is best categorized as a general Regulatory Filing (RNS), as it is a specific regulatory announcement that doesn't match the other defined types.
2016-01-08 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (December 31, 2015). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital structure, even though it is a monthly update rather than a specific transaction announcement. It is not a dividend notice (DIV), a director's dealing (DIRS), or a general regulatory filing (RNS) because it is highly specific to capital structure disclosure.
2016-01-08 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité IPSEN contracté avec NATIXIS" (Semi-annual balance sheet of the IPSEN liquidity contract with NATIXIS). It reports the status of a liquidity contract (likely a share buyback/stabilization agreement) as of December 31, 2015, comparing it to the previous semi-annual balance on June 30, 2015. This type of regular reporting on share transactions, often related to market making or stabilization, fits best under 'Transaction in Own Shares' (POS) or potentially a specialized financing/capital update. Given the context of a liquidity contract balance, POS (Report of the company buying back or selling its own shares) is the most precise fit, as liquidity contracts are mechanisms for managing share supply/demand, which involves transactions in own shares. It is not a general earnings release (ER), interim report (IR), or a general regulatory filing (RNS).
2016-01-06 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Regulatory Filings Classification · 99% confidence The document text is very short (662 characters) and details the status of a liquidity contract (share holdings and cash balance) as of two specific dates (December 31, 2015, and June 30, 2015). This type of regular update regarding share holdings, often related to market making or liquidity provision, is best classified under 'Transaction in Own Shares' (POS) as it directly relates to the company's own shares being held under a specific arrangement, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure. Given the specific nature of reporting on shares held under a liquidity contract, POS is the most precise fit among the options, as it deals with the company's own shares being managed in the market, distinct from insider trading (DIRS) or general capital changes (SHA). It is not a full financial report (IR/10-K) or an earnings announcement (ER).
2016-01-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.